Dystonia Drugs Sales

Dystonia Drugs Sales Market Outlook

The global dystonia drugs market is projected to reach approximately USD 2.5 billion by the year 2035, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2035. The increasing prevalence of dystonia, coupled with advancements in drug development and treatment options, is expected to drive this growth. Factors such as a rising aging population and the growing awareness regarding neurological disorders contribute significantly to the demand for effective dystonia treatments. Additionally, ongoing research and development efforts by pharmaceutical companies to introduce novel therapies are further fueling market expansion. The robust pipeline of drugs and the rising incidence of movement disorders are key drivers that will shape the future of the dystonia drugs market.

Growth Factor of the Market

The growth of the dystonia drugs market is significantly influenced by various factors. The increasing incidence of dystonia and other movement disorders, spurred by an aging population, has created a demand for effective pharmaceutical interventions. Furthermore, the rising investment in research and development by major pharmaceutical companies is paving the way for innovative and more effective treatment options, which enhances patient outcomes. The integration of advanced technologies in drug formulation and delivery systems is also a critical growth factor, as it improves the efficacy and safety profiles of the medications available for dystonia. Moreover, the increasing awareness regarding the availability of treatment options among healthcare professionals and patients is expected to drive market growth. Lastly, government initiatives aimed at promoting research in neurological disorders can create a conducive environment for the progression of the dystonia drugs market.

Key Highlights of the Market

• The global dystonia drugs market is expected to reach USD 2.5 billion by 2035.
• The market is anticipated to grow at a CAGR of 6.1% from 2025 to 2035.
• North America is expected to hold the largest market share, owing to advanced healthcare infrastructure.
• Botulinum Toxin is projected to dominate the drug type segment due to its effectiveness in treating various forms of dystonia.
• Online pharmacies are becoming increasingly popular, reflecting a trend towards digital healthcare solutions.

By Drug Type

Anticholinergics:

Anticholinergics are one of the pivotal drug types used in the treatment of dystonia. These medications work by blocking the action of acetylcholine, a neurotransmitter that can lead to involuntary muscle contractions associated with dystonia. They are particularly effective in younger patients, especially for those with primary generalized dystonia. While they can provide considerable relief from symptoms, the use of anticholinergics is often accompanied by side effects such as blurred vision, dry mouth, and constipation. The growing focus on individualized treatment plans and the development of more targeted therapies are expected to enhance the market segment for anticholinergics as part of the broader dystonia treatment landscape.

Dopamine Modulators:

Dopamine modulators play a significant role in the management of dystonia, particularly in patients with a primary dopaminergic deficiency. These medications work by adjusting the levels of dopamine in the brain, thereby mitigating symptoms associated with dystonia. They are widely prescribed in cases of secondary dystonia, where dopaminergic pathways are disrupted. The shift towards developing new generation dopamine modulators with improved safety profiles and fewer side effects is anticipated to bolster the market for this drug type. As research advances, the efficacy of these drugs is expected to improve, thus attracting a larger patient base.

Botulinum Toxin:

Botulinum toxin is among the most effective treatments for several forms of dystonia, including cervical dystonia and blepharospasm. This neurotoxin works by temporarily paralyzing the muscles that cause involuntary movements, providing significant relief from pain and discomfort. The rising adoption of botulinum toxin as a first-line therapy for focal dystonias has led to a substantial market share for this drug type. Ongoing research into the use of botulinum toxin for other forms of dystonia, along with improvements in injection techniques and dosing strategies, continues to enhance its appeal. The ability of this treatment to improve patients' quality of life significantly is a strong driver of its growth in the dystonia drugs market.

GABA Analogs:

GABA analogs have emerged as a viable option in the treatment of dystonia, primarily as adjunct therapy. These drugs work by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA), a neurotransmitter that helps regulate neuronal excitability and muscle contractions. The utility of GABA analogs, such as gabapentin, is particularly relevant in patients experiencing associated symptoms like anxiety and pain alongside dystonia. Although the market share for GABA analogs is currently smaller compared to other drug types, their potential in combination therapies points toward a growing recognition of their benefits, especially in complex cases of dystonia.

Others:

The "Others" segment encompasses various medications and treatment approaches that are not classified under the major drug types. This includes a range of experimental therapies, off-label medications, and herbal treatments. While these alternatives may not hold substantial market shares, they represent a growing interest in personalized medicine and the diversification of treatment options for dystonia. The increasing willingness of patients to explore complementary and alternative medicine reflects a broader trend in healthcare towards holistic approaches. As clinical trials advance and new findings are published, this segment may witness a gradual increase in its market presence.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are a crucial distribution channel for dystonia drugs, particularly due to their role in providing specialized care for patients with complex medical needs. These pharmacies often have access to a wide range of medications, including those that may not be available at retail outlets. Hospital pharmacists play a vital role in ensuring that medications are dispensed accurately and that patients receive appropriate counseling on their use. The increasing number of hospitals equipped with neurological departments is likely to enhance the demand for dystonia medications through hospital pharmacies over the forecast period. As healthcare systems evolve, the emphasis on integrated care will further boost this segment.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for dystonia medications, providing patients with convenient access to therapies prescribed by their healthcare providers. The availability of dystonia drugs in retail settings allows for greater patient autonomy and adherence to treatment regimens. With a growing focus on patient-centric services, many retail pharmacies are beginning to offer specialized consultations and support for patients managing chronic conditions like dystonia. The rise of pharmacy chains that prioritize neurological health and the introduction of awareness campaigns are expected to drive further growth in this distribution channel, making it a key player in the market landscape.

Online Pharmacies:

The prevalence and acceptance of online pharmacies have surged in recent years, particularly accelerated by the COVID-19 pandemic. This distribution channel offers the convenience of home delivery and the ability to compare prices and services easily. Online pharmacies have become an attractive option for patients seeking confidentiality and ease of access to dystonia medications. As regulations around online pharmacies continue to evolve, their credibility and safety are being reinforced, which, in turn, boosts consumer confidence. The ongoing technological advancements in e-commerce and telemedicine are anticipated to further expand the reach of online pharmacies, thereby increasing their market share in the dystonia drugs segment.

Others:

The "Others" distribution channel includes specialized clinics and compounding pharmacies that provide unique formulations of dystonia medications not available through traditional channels. These establishments often cater to specific patient populations with unique needs, such as those requiring personalized dosages or formulations due to allergies or sensitivities. The growth in precision medicine and tailored therapies is likely to encourage the expansion of this distribution channel. Patients seeking customized treatment options may increasingly turn to these specialized providers, thereby creating opportunities for niche players in the dystonia drugs market.

By Indication

Cervical Dystonia:

Cervical dystonia, a condition characterized by involuntary muscle contractions in the neck, represents a significant portion of the dystonia drugs market. The impact of cervical dystonia on patients' quality of life can be profound, leading to chronic pain and functional limitations. The availability of targeted therapies, including botulinum toxin injections, has significantly improved patient outcomes. As awareness regarding cervical dystonia increases, the demand for effective treatments is expected to rise correspondingly. Ongoing clinical research further aims to establish more effective treatment protocols, which will likely contribute to the growth of this indication segment.

Blepharospasm:

Blepharospasm, characterized by involuntary blinking or eyelid closure, affects a considerable segment of the population suffering from dystonia. The treatment landscape for blepharospasm includes various interventions, with botulinum toxin being the most commonly prescribed therapy. The efficacy of botulinum toxin in managing blepharospasm has been well-documented, leading to an increased market share for this indication. The rising demand for effective and safer treatment options is expected to promote research initiatives aimed at improving therapies for blepharospasm, thereby enhancing overall market growth.

Oromandibular Dystonia:

Oromandibular dystonia is characterized by involuntary movements of the jaw and facial muscles, which can lead to significant discomfort and difficulties in eating and speaking. The market for medications targeting this condition is steadily evolving, with a growing focus on the efficacy of botulinum toxin injections as a frontline treatment. Increased recognition of oromandibular dystonia within the medical community is likely to enhance treatment options and foster advancements in drug development. Collaborative efforts between healthcare providers and researchers are essential for elevating awareness and improving therapeutic strategies for this indication.

Writer's Cramp:

Writer's cramp, a task-specific dystonia affecting the hand muscles, poses unique challenges for affected individuals, particularly in academic and professional settings. The market for dystonia medications addressing writer's cramp includes both pharmacological and non-pharmacological approaches. Botulinum toxin has shown promise in alleviating symptoms, while physical therapy and occupational therapy also play key roles in treatment. As the population of individuals requiring effective management for writer's cramp continues to grow, the demand for innovative therapies and comprehensive treatment plans is expected to expand this indication segment.

Others:

This segment encompasses various atypical forms of dystonia and cases that do not fit the traditional definitions of the aforementioned types. Medications for these conditions may include off-label prescriptions and experimental drugs being tested in clinical trials. As research continues to uncover the complexities of dystonia and its various presentations, the market for these "Others" indications is anticipated to witness growth. Ongoing studies and the development of specialized treatment protocols are likely to provide new insights and therapeutic avenues for patients with less common forms of dystonia.

By End User

Hospitals:

Hospitals are a primary end-user segment in the dystonia drugs market, providing comprehensive care for patients with complex neurological disorders. These institutions typically have access to a wide range of medications, specialized services, and multidisciplinary treatment teams. Hospital-based treatment programs often include neurology specialists, physical therapists, and occupational therapists, offering a holistic approach to managing dystonia. The increasing number of specialized neurology departments within hospitals is likely to drive the demand for dystonia medications significantly, as well as foster advancements in treatment protocols tailored to individual patient needs.

Clinics:

Clinics specializing in neurological care also represent a significant end user of dystonia drugs. These facilities provide outpatient services and often focus on specific patient populations, such as those with movement disorders. The accessibility of clinics allows for easier follow-up visits and continuity of care, which is essential for managing chronic conditions like dystonia effectively. The growing number of dedicated movement disorder clinics is expected to enhance the segment's market reach. Ongoing collaborations between clinics and pharmaceutical companies may lead to more effective treatment plans and improved patient outcomes.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) have gained prominence as end users in the dystonia drugs market, particularly for patients requiring procedures such as botulinum toxin injections. These centers provide a cost-effective and efficient alternative to traditional hospital settings, allowing patients to undergo outpatient procedures with minimal disruption. As ASCs continue to expand and adopt advanced technologies, the appeal of receiving treatment in a more convenient setting is expected to drive growth in this end-user segment. The increasing acceptance of outpatient therapies among patients is likely to contribute to the expansion of ASCs as a key player in the dystonia drugs landscape.

Others:

The "Others" end-user segment includes various alternative healthcare settings, such as rehabilitation centers and home healthcare services. These facilities offer unique approaches to managing dystonia, focusing on enhancing patients' quality of life through supportive therapies and interventions. The rise of home-based care models, particularly in response to the ongoing healthcare shifts towards patient-centric care, is likely to drive demand for dystonia medications within this segment. As healthcare systems evolve, the emphasis on providing comprehensive care across diverse settings will enhance the appeal of this market category.

By Region

The regional analysis of the dystonia drugs market reflects significant variations in market dynamics and growth opportunities. North America is expected to dominate the market, accounting for approximately 45% of the global share in 2035. This growth can be attributed to the presence of advanced healthcare infrastructure, a high prevalence of neurological disorders, and significant investment in research and development. Furthermore, the trend towards the adoption of innovative therapies, such as botulinum toxin for various forms of dystonia, will continue to drive market expansion in this region. The compound annual growth rate (CAGR) for North America during the forecast period is projected to be around 6.5%, indicating a healthy growth trajectory fueled by ongoing advancements in pharmaceutical therapies and healthcare delivery.

Europe is anticipated to hold the second-largest market share, accounting for nearly 30% of the global dystonia drugs market by 2035. The region benefits from a robust healthcare system, increased awareness of dystonia, and growing investments in neurological research. Countries like Germany, France, and the United Kingdom are leading the charge in terms of drug development and providing comprehensive care for patients with dystonia. The CAGR for the European market is projected to be around 5.8% during the forecast period, as public and private partnerships continue to focus on addressing the unmet needs of patients with movement disorders. Meanwhile, the Asia Pacific region is expected to witness the most rapid growth, driven by increasing healthcare access, rising economic development, and a growing population seeking medical care for neurological conditions.

Opportunities

The dystonia drugs market presents numerous opportunities, primarily driven by advancements in research and the demand for personalized medicine. As pharmaceutical companies invest heavily in the development of novel therapies, new treatment options are expected to emerge, addressing various forms of dystonia more effectively. The rising awareness among healthcare providers and patients regarding available treatments is also expected to create a conducive environment for market growth. Additionally, the ongoing evolution of telemedicine and digital health is opening doors for more accessible consultations and treatment adherence support. This technological shift not only enhances patient engagement but also allows for a more integrated approach to managing dystonia, thereby increasing the market's potential. Furthermore, collaborative efforts between academic institutions and pharmaceutical companies can lead to innovative clinical trials that explore the efficacy of new drug candidates.

Another notable opportunity lies in increasing investment in healthcare infrastructure globally, particularly in emerging markets. As countries like India and China continue to enhance their healthcare systems, access to essential medications and specialized treatments for dystonia is expected to improve significantly. This growing access can lead to higher patient enrollment in treatment programs, thereby driving market growth. Additionally, the trend towards holistic and multidisciplinary care in managing neurological disorders is likely to offer avenues for integrated treatment approaches that include pharmacological therapy, physical rehabilitation, and psychological support. Such comprehensive care models can significantly improve patient outcomes and enhance the overall appeal of dystonia drugs.

Threats

Despite the promising outlook for the dystonia drugs market, several threats could hinder progress. One of the primary concerns is the stringent regulatory environment governing drug approvals and market access. Delays in the approval process for new drugs can stall innovation and limit the availability of potential therapies for patients. Additionally, the high costs associated with drug development and the increasing pressure on pharmaceutical companies to produce cost-effective treatments can pose challenges to market growth. Competition from alternative treatment options, including physical therapy and lifestyle interventions, may further disrupt the market landscape. The availability of generic alternatives could also lead to price erosion, impacting revenue generation for established pharmaceutical companies.

Moreover, the variability in patient response to dystonia treatments presents a hurdle in achieving optimal outcomes. The complexity of dystonia as a condition necessitates highly individualized treatment plans, which can complicate the prescribing process. This variability may also lead to dissatisfaction among patients if their treatment regimens do not yield expected results. Additionally, healthcare disparities, particularly in underserved populations, can limit access to effective medications and care, further exacerbating the challenges in managing dystonia. Continuous efforts will need to be made by stakeholders to address these issues and ensure equitable access to treatments.

Competitor Outlook

• AbbVie Inc.
• Allergan plc
• Boehringer Ingelheim GmbH
• Ipsen S.A.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Horizon Therapeutics plc
• Neurocrine Biosciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• Revance Therapeutics, Inc.
• Acorda Therapeutics, Inc.
• Apotex Inc.
• Merck & Co., Inc.
• Sientra, Inc.

The competitive landscape of the dystonia drugs market is characterized by a mix of established pharmaceutical giants and emerging biotech firms. Major players like AbbVie Inc. and Allergan plc dominate the market, particularly with their strong portfolios of botulinum toxin products, which have become the standard of care for focal dystonias. These companies invest heavily in research and development to innovate and expand their product offerings, ensuring they remain at the forefront of the market. Furthermore, collaborations and partnerships among companies and research institutions are becoming increasingly common, facilitating the development of new therapies and enhancing market competitiveness.

Emerging companies like Neurocrine Biosciences, Inc. are also gaining traction in the dystonia drugs market with their novel approaches to treatment. Their commitment to advancing the understanding of movement disorders and developing new therapeutic options positions them well for future growth. Such firms often focus on niche areas or specific patient populations, allowing them to differentiate themselves from larger competitors. The dynamic nature of the market encourages continuous innovation, creating opportunities for both established and emerging players to thrive.

As the market evolves, companies are also exploring the potential of combination therapies that integrate pharmacological treatments with physical and behavioral interventions. This trend emphasizes the growing recognition of a multidisciplinary approach to managing dystonia, which could enhance overall patient outcomes. The competitive landscape will also be shaped by ongoing collaborations, mergers, and acquisitions, as firms seek to expand their capabilities and reach within this market. Overall, the dystonia drugs market is poised for growth, driven by innovation, research, and the commitment of key stakeholders to address the needs of patients.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Ipsen S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Mylan N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Apotex Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sientra, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Horizon Therapeutics plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Acorda Therapeutics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim GmbH
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Revance Therapeutics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Neurocrine Biosciences, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Dystonia Drugs Sales Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Ambulatory Surgical Centers
    • 6.1.4 Others
  • 6.2 Dystonia Drugs Sales Market, By Drug Type
    • 6.2.1 Anticholinergics
    • 6.2.2 Dopamine Modulators
    • 6.2.3 Botulinum Toxin
    • 6.2.4 GABA Analogs
    • 6.2.5 Others
  • 6.3 Dystonia Drugs Sales Market, By Indication
    • 6.3.1 Cervical Dystonia
    • 6.3.2 Blepharospasm
    • 6.3.3 Oromandibular Dystonia
    • 6.3.4 Writer's Cramp
    • 6.3.5 Others
  • 6.4 Dystonia Drugs Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Dystonia Drugs Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Dystonia Drugs Sales market is categorized based on

By Drug Type

• Anticholinergics
• Dopamine Modulators
• Botulinum Toxin
• GABA Analogs
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Indication

• Cervical Dystonia
• Blepharospasm
• Oromandibular Dystonia
• Writer's Cramp
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Allergan plc
• Boehringer Ingelheim GmbH
• Ipsen S.A.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Horizon Therapeutics plc
• Neurocrine Biosciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• Revance Therapeutics, Inc.
• Acorda Therapeutics, Inc.
• Apotex Inc.
• Merck & Co., Inc.
• Sientra, Inc.